ERBB2 and neoplasm: Intensive research on EGFR I and ErbB2 in tumor cells has led to successful therapeutic strategies targeting these receptors: Anti-EGFR molecules like cetuximab or gefitinib are used in colorectal cancer, lung cancer, head and neck carcinoma, and others.